/C O R R E C T I O N - LifeStance Health/
LifeStance Health published observational outcomes data showing 74% of esketamine patients and 61% of TMS patients achieved clinically meaningful depression-symptom reduction. The company is expanding access to both specialty treatments for treatment-resistant depression, a population it estimates at roughly 139,000 of its adult patients — about 28% of its depression patients. Suicidal ideation fell 85% among esketamine patients and 50% among TMS patients after treatment, per PHQ-9 tracking.
Key figures
- Tms patients analyzed
- 355
- Esketamine patients analyzed
- 258
- Trd pct of depressed patients
- 28%
- Total patients served annually
- more than one million
- Tms suicidal ideation reduction
- 50%
- Trd patients life stance annual
- 139000
- Tms clinically meaningful response
- 61%
- Esketamine suicidal ideation reduction
- 85%
- Esketamine clinically meaningful response
- 74%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.